A long and successful heritage in China

GSK's history in China can be traced back to the early 20th century. Since the 1980s, GSK has actively invested in China by contributing state-of-the-art pharmaceutical technologies, innovative products, new business models, modern management concepts and sales and marketing skills.

Since the completion of the global merger between Glaxo Wellcome and SmithKline Beecham in December 2000, GSK has maintained a leading position within the pharmaceutical community. In 2002, GlaxoSmithKline (China) Investment Co. Ltd. was officially established and became one of the largest multinational pharmaceutical companies in China.

Among its major business units in China, Prescription Medicines, Vaccines, Over-the-Counter (OTC) Medicines and Consumer Healthcare are headquartered separately in Shanghai, Tianjin and Hong Kong. Beijing is also the base and area centre for the holding company GlaxoSmithKline (China) Investment Co. Ltd.

GSK is one of the first foreign pharmaceutical companies to establish successful joint ventures in China. To date, more than twenty years after its initial investment in China, GSK has established five companies with a total registered capital of US$230 million. The various companies continue to create jobs and provide training for business managers and professional staff in the pharmaceutical industry, as well as provide business opportunities to local partners and medical professionals.

Currently, GSK China has offices in twenty-eight major cities (including Hong Kong) and five legal entities encompassing four manufacturing facilities, two joint ventures and near 3000 employees nationwide.